‘Five Pillars’ For US Supplement GMP Compliance Are ‘No Surprise’ But Also Commonly Missed
“If we start seeing crumbling in multiple of them, that's where an investigator is going to really start digging and say, is this an issue with one product or one situation, maybe just one column, so maybe the batch production records are incomplete?” says Siobhan Gallagher Taylor in FDA’s OII.
HBW Insight - July 3, 2026

Medtech’s 2026 Cybersecurity Breaches Spared The Devices — And Hammered Everything Else
In 2026, medtech's cyber defenses cracked one after another — exposing an industry caught between legacy systems it cannot patch and new digital tools it hasn't secured.
Medtech Insight - July 3, 2026

Dyne CEO On Establishing A Pure-Play Neuromuscular Company
Dyne Therapeutics CEO John Cox talked to Scrip about the company’s upcoming transition to the commercial stage and why its exon-skipping drug z-rostudirsen can do what Sarepta’s Exondys can’t.
Scrip - July 3, 2026

Ipsen Digging Hard To Find Diamonds In The Rough
The acquisitions of Memo and Kartos that the French firm sealed within three days highlights its ability to secure clinical gems that others miss, chief business officer Philippe Lopes-Fernandes tells Scrip.
Scrip - July 3, 2026

Deal Watch: Boehringer Ingelheim Unveils Cancer Pacts With Immunai And Combotope
Plus deals involving Metis/Boulevard, SK/JH2, Elixirgen/Nippon Shinyaku, Debiopharm/Peptron, April Bio/TKG Group/IMM Investment Fund, Lilly/Abbisko, Lilly/Innovent, Bionyra/TrueLab, Antengene/K2 and more.
Scrip - July 3, 2026

Altimmune Readies Phase III MASH Plans With Dual GLP-1/GCG Agonist
Altimmune will start a Phase III MASH study for pemvidutide this year, but Lilly’s triple agonist retatrutide and dual GLP-1/GCG agonists at Merck and Boehringer Ingelheim loom as competition.
Scrip - July 3, 2026

FDA Classifies Insulet’s Omnipod Correction As Class I Recall Over Cannula Defect
The FDA has classified Insulet's voluntary correction of ~7 million Omnipod pods as a Class I recall over a cannula-tear defect that can cause undetected insulin under-delivery and, in severe cases, DKA. Insulet reports 24 serious adverse events, no deaths, and up to $50m in 2026 costs.
Medtech Insight - July 3, 2026

Dr Reddy’s Chief On Gains From gRevlimid, Patient Capital To Drive Innovation In India
Satish Reddy, chairman of Dr Reddy's Laboratories, talks about deploying generic Revlimid gains strategically, building a diversified growth engine, what India must fix — regulatory science, risk capital and more — to become a serious innovation force and learnings from China.
Scrip - July 3, 2026

Prestige Biopharma And Charles River Align On Biosimilar Development
Prestige Biopharma and Charles River Laboratories have signed a MoU establishing a mutual client referral arrangement to accelerate biosimilar development.
Generics Bulletin - July 3, 2026

Celltrion Leads The Way In US With Interchangeable Rituximab Biosimilar??
Celltrion has strengthened its position in the US rituximab biosimilar market with the announcement of interchangeability status for its Teva-partnered Truxima version.??
Generics Bulletin - July 3, 2026

Sandoz’s Direct-to-Patient Platform Is First Step In Long-Term DTP Strategy
Sandoz has launched a “Sandoz Direct” US direct-to-patient platform, with somatropin biosimilar Omnitrope as its first product. The company told Generics Bulletin that the platform marked just the first step in building a long-term DTP capability, with further products expected to be added.
Generics Bulletin - July 3, 2026

Cancer Drug Suppliers In Limelight As Oxaliplatin Added To US List Of Shortages
Oncology drug suppliers like Fresenius Kabi, Sandoz, Teva, Dr. Reddy’s and Aurobindo are in the spotlight as they hold keys to solving a deepening cancer drugs shortage crisis in US, EU, Australia, Canada and India, amid originator brand discontinuations and structural issues
Scrip - July 3, 2026

Finance Watch: Abivax, Definium Keep The Large Follow-On Offering Momentum Going
Public Company Edition: Abivax raised $920m and Definium brought in $805m from follow-on public offerings, continuing a trend of large FOPOs after positive data. Also, Ligand sold $700m worth of notes, PTC priced a $500m note offering and Dyne expanded its debt facility to $400m.
Scrip - July 3, 2026

KM Biologics Balances Domestic Hemophilia Demand With Export Ambitions
KM Biologics is pursuing Japanese export approval for its hemophilia product Byclot while needing to meet requirements for uninterrupted domestic supplies, in line with Japan's self-sufficiency priorities.
Scrip - July 3, 2026

Executives On The Move: Takeda’s Julie Kim Among Four New CEOs This Week
Recent moves in the industry include changes at the top at Oryn Therapeutics and internal moves at Vyriad and Shanghai Pharmaceuticals, plus Candel Therapeutics gets a new CCO from AstraZeneca.
Scrip - July 3, 2026

AstraZeneca Partners With CSPC Again, For siRNAs In Renal Diseases
AstraZeneca and CSPC Pharmaceutical add to their multiple collaborations for early-stage assets supported by the Chinese firm’s AI-driven platforms, this time for siRNA therapies in renal diseases.
Scrip - July 3, 2026

Plaintiffs Say Stimulator Makers Used FDA Supplement Pathway To Avoid New Trials
A federal panel has centralized 14 spinal cord stimulator suits against Boston Scientific in California, as plaintiffs allege manufacturers used incremental FDA supplement filings to overhaul Class III devices without new safety trials. Separate MDLs for Abbott and Nevro are planned.
Medtech Insight - July 3, 2026

Chinese Autoimmune Disease Assets Shine In Latest VC/PE Funding Deals
Artivila, LyncBio, Angel and Accro are among the Chinese biopharma ventures recently raising fresh capital from venture capital and private equity investors, for assets targeting rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis and ulcerative colitis, among others.
Scrip - July 3, 2026

US Consumer Health Industry News Digest: Business, Regulation, Science
FTC wants AI policy statement input; CRN completes filing briefs with Supreme Court on New York law challenge; NIH announces Supplements Facts First Challenge phase 1 winners; and HBW Insight publishes article packages from AESGP meeting in Berlin and US OTC sunscreen ingredient approval.
HBW Insight - July 3, 2026